Alex R. Thurman Sells 1,520 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 1,520 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total transaction of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares of the company’s stock, valued at $5,708,568.04. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Glaukos Stock Performance

Shares of Glaukos stock opened at $101.97 on Friday. The firm has a market cap of $5.77 billion, a PE ratio of -35.53 and a beta of 0.99. Glaukos Co. has a 1 year low of $88.16 and a 1 year high of $163.71. The firm’s 50-day simple moving average is $130.52 and its 200-day simple moving average is $135.64. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The firm had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Equities analysts forecast that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GKOS. Stephens raised Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. Morgan Stanley lowered Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a research note on Monday, December 2nd. Stifel Nicolaus raised their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Truist Financial boosted their price objective on Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Finally, Needham & Company LLC increased their target price on Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $163.25.

Hedge Funds Weigh In On Glaukos

A number of hedge funds have recently added to or reduced their stakes in GKOS. IFP Advisors Inc acquired a new stake in shares of Glaukos during the fourth quarter worth $43,000. Asset Planning Inc bought a new stake in shares of Glaukos during the 4th quarter valued at about $90,000. CoreCap Advisors LLC raised its stake in Glaukos by 36.4% during the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock worth $112,000 after acquiring an additional 200 shares during the period. Harvest Fund Management Co. Ltd lifted its holdings in Glaukos by 2,263.2% in the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after acquiring an additional 860 shares during the last quarter. Finally, Picton Mahoney Asset Management acquired a new position in Glaukos in the fourth quarter valued at approximately $125,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.